Ananda Developments Past Earnings Performance

Past criteria checks 0/6

Ananda Developments's earnings have been declining at an average annual rate of -54%, while the Pharmaceuticals industry saw earnings growing at 10.8% annually.

Key information

-54.0%

Earnings growth rate

-16.1%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth raten/a
Return on equity-1,750.6%
Net Marginn/a
Last Earnings Update31 Jan 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Ananda Developments makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BST:1FX Revenue, expenses and earnings (GBP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Jan 240-620
31 Oct 230-420
31 Jul 230-210
30 Apr 230-110
31 Jan 230-110
31 Oct 220-110
31 Jul 220-110
30 Apr 220-110
31 Jan 220-110
31 Oct 210-110
31 Jul 210-110
30 Apr 210-110
31 Jan 210000
31 Oct 200000
31 Jul 200000
30 Apr 200000
31 Jan 200000
31 Oct 190000
31 Jul 190-110
30 Apr 190000

Quality Earnings: 1FX is currently unprofitable.

Growing Profit Margin: 1FX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 1FX is unprofitable, and losses have increased over the past 5 years at a rate of 54% per year.

Accelerating Growth: Unable to compare 1FX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1FX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.5%).


Return on Equity

High ROE: 1FX has a negative Return on Equity (-1750.65%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies